KPTI · Karyopharm Therapeutics Inc.
$6.86
-0.24 (-3.31%)
At close · Jul 29
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed May 14, 2026
Market Cap
$160.68M
Shares
22.66M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$146.07M
+0.6%
FY2025
Net Income
-$196.04M
-156.5%
FY2025
Operating Margin
-62.1%
+20.1pp
FY2025
Diluted EPS
-$17.93
-28.1%
FY2025
Operating Cash Flow
-$75.37M
+40.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $130M – $150M | $151.12M | $146.07MG | $145.24M | $146.03M | $157.07M | $209.82M | $108.09M | $40.89M | $30.34M | $1.61M | $154K | $250K | $229K | $387K | $634K | $152K | — | — | |
| — | $124.8M | $125.62M | $143.23M | $138.75M | $148.66M | $160.84M | $150.81M | $122.34M | $161.37M | $107.27M | $86.94M | $97.74M | $60.13M | $28.45M | $14.1M | $8.62M | — | — | |
| — | $83.5M | — | — | — | — | — | — | — | $48.85M | $24.87M | $23.95M | $21.58M | $15.95M | $5.89M | $2.43M | $1.84M | — | — | |
| — | $104.54M | $105.21M | $115.44M | $131.88M | $145.4M | $143.85M | $126.42M | $105.42M | $48.85M | $24.87M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $974K | $735K | $713K | $717K | $634K | $323K | $144K | $122K | $83K | — | — | |
| — | $235.33M | $236.77M | $264.68M | $275.57M | $299.28M | $308.09M | $279.94M | $230.17M | $210.22M | $132.14M | $110.89M | $119.33M | $76.08M | $34.34M | $16.52M | $10.46M | — | — | |
| — | -$84.21M | -$90.71M | -$119.44M | -$129.54M | -$142.2M | -$98.27M | -$171.85M | -$189.28M | -$179.88M | -$130.54M | -$110.73M | -$119.08M | -$75.85M | -$33.95M | -$15.89M | -$10.31M | — | — | |
| — | — | -62.1% | -82.24% | -88.71% | -90.53% | -46.84% | -159% | -462.85% | -592.97% | -8133.21% | -71903.9% | -47630.4% | -33120.52% | -8772.61% | -2506.31% | -6783.55% | — | — | |
| — | — | — | — | — | — | — | — | -$188.3M | -$179.15M | -$129.83M | -$110.02M | -$118.44M | -$75.52M | -$33.81M | -$15.77M | -$10.23M | — | — | |
| — | $47.41M | $45.85M | $37.42M | $23.82M | $25M | $26.05M | $27.14M | $15.65M | $2.49M | — | — | — | $1000 | $188K | — | — | — | — | |
| — | $2.28M | $2.77M | $7.4M | $10.94M | $2.36M | $582K | $2.82M | $5.42M | $4.03M | $1.7M | $1.28M | $897K | $97K | $3000 | $2000 | — | — | — | |
| — | -$110.75M | -$105.29M | $43.08M | -$13.24M | -$22.72M | -$25.55M | -$24.11M | -$10.28M | $1.5M | $1.62M | $1.29M | $895K | $69K | $3000 | $2000 | — | — | — | |
| — | -$194.96M | -$196M | -$76.37M | -$142.78M | -$164.92M | -$123.82M | -$195.96M | -$199.55M | -$178.38M | -$128.92M | -$109.44M | -$118.18M | -$75.78M | — | — | — | — | — | |
| — | $8000 | $43K | $57K | $323K | $369K | $268K | $309K | $40K | $26K | $63K | $139K | -$118.09M | -$75.78M | -$33.95M | -$15.89M | — | — | — | |
| — | -$194.97M | -$196.04M | -$76.42M | -$143.1M | -$165.29M | -$124.09M | -$196.27M | -$199.59M | -$178.41M | -$128.98M | -$109.58M | -$118.18M | -$75.78M | -$33.95M | -$15.89M | — | — | — | |
| — | — | -134.21% | -52.62% | -97.99% | -105.23% | -59.14% | -181.59% | -488.08% | -588.1% | -8036.39% | -71153.9% | -47272.4% | -33090.39% | -8771.83% | -2505.99% | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -$75.78M | -$33.95M | -$15.89M | -$10.31M | -$2.24M | -$179K | |
| — | -$194.61M | -$195.61M | -$76.62M | -$142.62M | -$166.12M | -$124.42M | -$195.72M | -$199.38M | -$178.43M | -$128.93M | -$109.57M | -$118.43M | -$75.81M | -$33.95M | -$15.89M | — | — | — | |
| USD/shares | — | — | -$17.93 | -$9.41 | -$18.79 | -$30.30 | -$24.75 | -$40.80 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | -$17.93 | -$14.00 | -$18.79 | -$30.30 | -$24.75 | -$40.80 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 10.94K | 8125 | 7616 | 5458.0667 | 5.01M | 4.8M | 4.13M | 3785.3333 | 3.06M | 2.5M | 2.37M | 2.08M | 404.51K | 118.35K | 66.94K | — | — |
| shares | — | — | 10.94K | 8455 | 7616 | 5458.0667 | 5.01M | 4.8M | 4.13M | 3785.3333 | 3.06M | 2.5M | 2.37M | 2.08M | 404.51K | 118.35K | 66.94K | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.85×
EV/EBIT
—
Peer median 26.86×
P/E (TTM)
—
Peer median 4.43×
Peer medians compare against the 298 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $114,857,000 | $112,806,000 | $112,011,000 | $120,445,000 | $98,436,000 | $76,210,000 | $30,540,000 | $0 |
| License and Other | $31,210,000 | $32,431,000 | $34,022,000 | $36,629,000 | $111,383,000 | $31,875,000 | $10,353,000 | $30,336,000 |
Key facts
CIK
1503802
CUSIP
48576U205
13F (30d)
10 filings
10 filers
Visit website
Investor relations